Boardroom Alpha
10-K primary document
UTHR · Annual Report (Form 10-K) · Filed February 25, 2026

United Therapeutics Corp10-K exhibit

uthrexh10561231202510k.htm
Document
Exhibit 10.56

NINTH AMENDMENT
TO
SPECIALTY PHARMACY NETWORK AGREEMENT

This Ninth Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referred to in this Agreement as a “Party,” collectively, the “Parties.”

WHEREAS, the Parties entered into that certain Specialty Pharmacy Network Agreement dated as of January 1, 2018, as amended (the “Agreement”); and

WHEREAS, the Parties entered into that certain Master Services Agreement dated December 18, 2013 as amended (the “Master Services Agreement”); and

NOW THEREFORE, in consideration of the mutual agreements and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows:

1.Attachment A. Attachment A is hereby deleted in its entirety and is replaced with the Attachment A attached hereto.

2.Attachment E. Attachment E is hereby deleted in its entirety and is replaced with the Attachment E attached hereto.

3.Except as amended and supplemented hereby, all of the terms and conditions of the Agreement shall remain and continue in full force and effect and apply hereto.

IN WITNESS WHEREOF, each of the undersigned, duly authorized, has executed this Amendment, effective as of the Amendment Effective Date.


Accredo Health Group, Inc.

By:    /s/ Michael Hughes
    
Print Name: Michael Hughes
    
Title:    Managing Director
    
Date: 11/10/2025
United Therapeutics Corporation

By:    /s/ Chip Jackson
    
Print Name: Chip Jackson
    
Title:    VP Distribution and Patient Access
    
Date: 13-Nov-2025 | 9:47:09 AM EST









Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer